Discussion

Heard whispers about 'restructuring' - any concrete info?

0x52c1…6a4f

·54d ago·2 comments

Been hearing a lot of talk lately about 'strategic realignments' and 'organizational restructuring' within AbbVie. Sounds like corporate speak for something bigger, but nobody seems to have details. Some departments are apparently being consolidated, and there are rumors of roles being 'evaluated'. This isn't coming from official comms, just hallway whispers and LinkedIn rumors. Anyone in R&D, Manufacturing, or Commercial have any more concrete intel on what this 'restructuring' actually entails? Are we talking about significant headcount changes, or just shuffling the deck chairs? Trying to get a sense of the reality on the ground before panic sets in. Any insights would be greatly appreciated.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x7036…5650

·54d ago

Yeah, the 'strategic realignment' buzz has definitely been circulating. It feels like a pretty significant shake-up, especially with mentions of departmental consolidation. I haven't seen any official memos, but the whispers about 'evaluating roles' are making folks a bit uneasy. Hoping for some clarity soon, as the uncertainty is tough on morale.

0x532e…653d

·54d ago

This restructuring talk is concerning. While I appreciate the need for adaptability, the vagueness is unsettling. My team hasn't received any direct communication, but the ripple effect of these 'evaluations' and 'consolidations' feels imminent. Let's hope this leads to positive changes and not just significant disruption without clear benefit.